Cross-Sector entity
Every one of those 1 sits in a single category, medical-devices. Austin Aerts is most often covered alongside PRIME study, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention Austin Aerts, all published on March 19, 2026.
1 verified story tracked
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, medical-devices. Austin Aerts is most often covered alongside PRIME study, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention Austin Aerts, all published on March 19, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Austin Aerts. Shared-story counts are live from our verified record — not editorial picks.
Runway Horizon
Current capital projected to fund operations through significant commercial milestones.
2026 Target
Goal to reach 15-17 states and operate 5-7 live partner programs.
Q4 Earnings Call
Management outlines pivot from R&D to commercial scaling and state-level engagement.
Fiscal Year End
Sera concludes 2025 with $95.8M cash and successful PRIME study publication.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.
